miR-218-5p and miR-320a-5p as Biomarkers for Brain Disorders: Focus on the Major Depressive Disorder and Parkinson’s Disease

[1]  Yaguo Gong,et al.  Classification for psychiatric disorders including schizophrenia, bipolar disorder, and major depressive disorder using machine learning , 2022, Computational and structural biotechnology journal.

[2]  Guiying Wang,et al.  Integrated co-expression network analysis uncovers novel tissue-specific genes in major depressive disorder and bipolar disorder , 2022, Frontiers in Psychiatry.

[3]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[4]  J. Peedicayil.  The relevance of polycomb group proteins to the development of psychiatric disorders , 2022, Frontiers in Cell and Developmental Biology.

[5]  N. Hoshina,et al.  ASD/OCD-Linked Protocadherin-10 Regulates Synapse, But Not Axon, Development in the Amygdala and Contributes to Fear- and Anxiety-Related Behaviors , 2022, The Journal of Neuroscience.

[6]  Madiha Rasheed,et al.  A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis , 2022, International journal of molecular sciences.

[7]  Yulin Deng,et al.  Epigenetic Regulation of Neuroinflammation in Parkinson’s Disease , 2021, International journal of molecular sciences.

[8]  Sonja W. Scholz,et al.  Challenges in the diagnosis of Parkinson's disease , 2021, The Lancet Neurology.

[9]  W. L. Lim,et al.  MicroRNA Dysregulation in Parkinson’s Disease: A Narrative Review , 2021, Frontiers in Neuroscience.

[10]  N. Jaafari,et al.  On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? , 2021, Journal of neuroinflammation.

[11]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[12]  Yan Cheng,et al.  Down regulation of miR‐218, miR‐124, and miR‐144 relates to Parkinson's disease via activating NF‐κB signaling , 2020, The Kaohsiung journal of medical sciences.

[13]  C. Caltagirone,et al.  Drug Choices and Advancements for Managing Depression in Parkinson's Disease , 2020, Current neuropharmacology.

[14]  A. Yang,et al.  Role of Interleukin-6 in Depressive Disorder , 2020, International journal of molecular sciences.

[15]  D. Aarsland,et al.  Combinatory microRNA serum signatures as classifiers of Parkinson's disease. , 2019, Parkinsonism & related disorders.

[16]  M. Ryan,et al.  Drug treatment strategies for depression in Parkinson disease , 2019, Expert opinion on pharmacotherapy.

[17]  E. Nestler,et al.  MiR-218: A Molecular Switch and Potential Biomarker of Susceptibility to Stress , 2019, bioRxiv.

[18]  R. Sagar,et al.  Serum S100B levels in patients with depression , 2019, Indian Journal of Psychiatry.

[19]  P. Lingor,et al.  Circulating miRNAs as Diagnostic Biomarkers for Parkinson’s Disease , 2018, Front. Neurosci..

[20]  J. Ioannidis,et al.  Meta-analyses identify differentially expressed microRNAs in Parkinson’s disease , 2018, bioRxiv.

[21]  M. Hallett,et al.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[22]  Nadeeka Dissanayaka,et al.  Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature , 2017, Journal of geriatric psychiatry and neurology.

[23]  M. Fava,et al.  Circulating microRNAs as biomarkers for depression: Many candidates, few finalists. , 2017, Journal of affective disorders.

[24]  E. Nestler,et al.  DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218 , 2017, Biological Psychiatry.

[25]  A. Xie,et al.  Plasma levels of miR-137 and miR-124 are associated with Parkinson’s disease but not with Parkinson’s disease with depression , 2017, Neurological Sciences.

[26]  Karin E. Borgmann-Winter,et al.  Sociability Deficits and Altered Amygdala Circuits in Mice Lacking Pcdh10, an Autism Associated Gene , 2017, Biological Psychiatry.

[27]  S. Russo,et al.  Integrating Interleukin-6 into depression diagnosis and treatment , 2016, Neurobiology of Stress.

[28]  L. Tamer,et al.  Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls. , 2015, Journal of psychiatric research.

[29]  S. Himelhoch,et al.  Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. , 2015, Parkinsonism & related disorders.

[30]  D. Bartel,et al.  Predicting effective microRNA target sites in mammalian mRNAs , 2015, eLife.

[31]  R. Cui.  EDITORIAL A Systematic Review of Depression , 2015, Current neuropharmacology.

[32]  A. Serretti,et al.  Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications , 2015, Current Psychiatry Reports.

[33]  Chung-Yen Lin,et al.  cytoHubba: identifying hub objects and sub-networks from complex interactome , 2014, BMC Systems Biology.

[34]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[35]  Jeremiah R. Brown,et al.  Blood Levels of S-100 Calcium-Binding Protein B, High-Sensitivity C-Reactive Protein, and Interleukin-6 for Changes in Depressive Symptom Severity after Coronary Artery Bypass Grafting: Prospective Cohort Nested within a Randomized, Controlled Trial , 2014, PloS one.

[36]  P. Lun,et al.  Targeted Suppression of Chaperone-Mediated Autophagy by miR-320a Promotes α-Synuclein Aggregation , 2014, International journal of molecular sciences.

[37]  L. Marsh,et al.  Depression and Parkinson’s Disease: Current Knowledge , 2013, Current Neurology and Neuroscience Reports.

[38]  N. Bérubé,et al.  Chromatin Structure and Intellectual Disability Syndromes , 2013 .

[39]  W. Weiner,et al.  Quality improvement in neurology: AAN Parkinson disease quality measures , 2010, Neurology.

[40]  Hong Yuan 袁红,et al.  Treatment strategies for Parkinson’s disease , 2010, Neuroscience Bulletin.

[41]  S. Buyske,et al.  The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[42]  D. Aarsland,et al.  A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[43]  R. Dobkin,et al.  Cognitive‐behavioral therapy for depression in Parkinson's disease: A pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[44]  M. Giovannelli,et al.  Prodromal non-motor symptoms of Parkinson’s disease , 2007, Neuropsychiatric disease and treatment.

[45]  S. Sharfstein.  Quality improvement. , 2006, The American journal of psychiatry.

[46]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[47]  I. Katz,et al.  Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease , 2004, Journal of the American Geriatrics Society.

[48]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[49]  M. Wiesmann,et al.  S100B and response to treatment in major depression: a pilot study , 2003, European Neuropsychopharmacology.

[50]  D. Burn.  Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[51]  H. Grabe,et al.  Neurotrophic Factor S100beta in Major Depression , 2001, Neuropsychobiology.

[52]  K. Ulgen,et al.  Inflammatory response and its relation to sphingolipid metabolism proteins: Chaperones as potential indirect anti-inflammatory agents. , 2019, Advances in protein chemistry and structural biology.

[53]  Dag Aarsland,et al.  Depression in Parkinson disease—epidemiology, mechanisms and management , 2011, Nature Reviews Neurology.

[54]  Gary D Bader,et al.  BMC Bioinformatics Methodology article Statistical significance for hierarchical clustering in genetic association and microarray expression studies , 2003 .

[55]  Fabrizio Stocchi,et al.  Factors impacting on quality of life in Parkinson's disease: Results from an international survey , 2002, Movement disorders : official journal of the Movement Disorder Society.

[56]  H. Grabe,et al.  Neurotrophic factor S100 beta in major depression. , 2001, Neuropsychobiology.

[57]  D. Deeg,et al.  Depression in Parkinson's disease. The impact of symptom overlap on prevalence. , 1998, Psychosomatics.